All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients with relapsed Hodgkin lymphoma.1 There is a need for alternative consolidation strategies after auto-HSCT in patients at a high risk of relapse. As previously covered by the Lymphoma Hub, anti-CD30 chimeric antigen receptor (CAR) T-cell therapy could be a promising posttransplant consolidation therapy for patients with CD30+ Hodgkin and non-Hodgkin lymphoma who are at high risk of relapse.1
Recently, results were published from a phase I trial (NCT02663297) assessing the safety of anti-CD30 CAR T-cell therapy as consolidation after auto-HSCT in patients with high-risk CD30+ lymphoma by Grover et al. in The Lancet Haematology. We summarize the key findings below.
Table 1. Treatment-emergent adverse events*
Treatment-emergent adverse events, n |
Grade 1–2 |
Grade 3 |
Grade 4 |
Anemia |
1 |
1 |
0 |
Aspartate aminotransferase increased |
4 |
0 |
0 |
Cytokine release syndrome |
1 |
0 |
0 |
Diarrhea |
3 |
0 |
0 |
Dizziness |
2 |
0 |
0 |
Fatigue |
3 |
0 |
0 |
Headache |
2 |
0 |
0 |
Hypocalcemia |
2 |
0 |
0 |
Lymphocyte count decreased |
6 |
2 |
0 |
Nausea |
6 |
0 |
0 |
Neutrophil count decreased |
3 |
0 |
1 |
Platelet count decreased |
4 |
1 |
0 |
Rash maculopapular |
1 |
1 |
0 |
Vomiting |
2 |
0 |
0 |
White blood cell count decreased |
4 |
2 |
0 |
*Adapted from Grover, et al.1 |
Figure 1. 2-year progression-free survival and overall survival rates*
*Adapted from Grover, et al.
Key learnings |
|
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox